Scholar Rock (NASDAQ:SRRK) Trading Down 4.3% – Should You Sell?

Scholar Rock Holding Co. (NASDAQ:SRRK) shares fell 4.3% on Monday . The company traded as low as $43.04 and last traded at $43.21. 149,001 shares changed hands during trading, a decline of 73% from the average session volume of 552,993 shares. The stock had previously closed at $45.17.

Analyst Upgrades and Downgrades

Several analysts recently commented on SRRK shares. Wedbush lifted their price objective on Scholar Rock from $40.00 to $47.00 and gave the stock an “outperform” rating in a report on Monday, November 25th. HC Wainwright boosted their target price on shares of Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Piper Sandler increased their price target on shares of Scholar Rock from $28.00 to $42.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Truist Financial raised their target price on Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 25th. Finally, JPMorgan Chase & Co. upped their price target on Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, October 14th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Scholar Rock presently has an average rating of “Buy” and an average target price of $40.43.

Scholar Rock Stock Performance

The firm has a market capitalization of $4.06 billion, a P/E ratio of -18.48 and a beta of 0.52. The firm has a 50-day moving average price of $36.70 and a two-hundred day moving average price of $20.68. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Insider Transactions at Scholar Rock

In related news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the transaction, the insider now directly owns 10,850,005 shares in the company, valued at $417,616,692.45. The trade was a 3.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 19.20% of the company’s stock.

Institutional Trading of Scholar Rock

Several large investors have recently added to or reduced their stakes in SRRK. GAMMA Investing LLC increased its position in shares of Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after buying an additional 269 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Scholar Rock by 1.0% in the third quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock valued at $310,000 after purchasing an additional 379 shares in the last quarter. Exome Asset Management LLC acquired a new stake in shares of Scholar Rock in the third quarter valued at approximately $1,115,000. Barclays PLC lifted its position in Scholar Rock by 103.4% during the third quarter. Barclays PLC now owns 165,449 shares of the company’s stock worth $1,324,000 after buying an additional 84,118 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Scholar Rock by 8.5% in the third quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company’s stock valued at $12,361,000 after purchasing an additional 120,489 shares during the period. Hedge funds and other institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.